December 3, 2025
Research
Policy and Reimbursement Strategies to Improve Patient Access to Prescription Digital Therapeutics
The U.S. is falling behind in making FDA-cleared prescription digital therapeutics (PDTs) accessible to patients. In their new article in npj Digital Medicine, they highlight how outdated reimbursement policies are creating barriers — and why timely policy action, including a dedicated Medicare benefit, is critical to expanding access, reducing costs, and driving equitable, patient-centered digital care.
Digital therapeutics are transforming treatment for mental health, chronic disease, and more — but only if patients can actually reach them. ATA’s leaders lay out a roadmap to make that future a reality.
Authors:
Andy Molnar
Senior Vice President, Industry Affairs, ATA
Lani Reilly
Vice President, Industry Affairs, ATA

